The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 152.50
Bid: 150.00
Ask: 155.00
Change: -5.00 (-3.17%)
Spread: 5.00 (3.333%)
Open: 157.50
High: 157.50
Low: 152.50
Prev. Close: 157.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM Admission - First Day of Dealings

10 Jul 2012 08:05

RNS Number : 2577H
Revolymer PLC
10 July 2012
 



10 July 2012

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, THE REPUBLIC OF IRELAND, JAPAN OR AUSTRALIA

Revolymer plc

("Revolymer" or "the Group")

First day of dealings and completion of placing

Revolymer, the British polymer company developing products for a number of high value fast moving consumer goods (FMCG) markets, is pleased to announce that, further to its announcement on 4 July 2012, admission and unconditional dealings in its Ordinary Shares have commenced at 8.00am today on the AIM market of the London Stock Exchange plc ("Admission").

 

Revolymer also announces that the placing announced on 4 July 2012 ("Placing") has become unconditional in all respects.

 

Summary

·; Revolymer has placed a total of 25,000,000 ordinary shares ("Placing Shares") with institutional investors at a price of 100 pence per Placing Share ("Placing Price") to raise gross proceeds of £25.0 million.

·; Based on the Placing Price, the market capitalisation of Revolymer on Admission was approximately £53.0 million.

·; The number of ordinary shares in issue immediately after Admission is 53,015,170.

·; Revolymer will use the net proceeds of the Placing primarily to expand the distribution of the Group's confectionery gum products in the United States and into Europe, to fund additional regulatory dossiers in connection with its nicotine gum commercialisation, and to fund the development of its consumer specialties products.

·; The Group's trading symbol is "REVO" and ISIN code is GB00B84LVH87.

·; Panmure Gordon (UK) Limited ("Panmure Gordon") is acting as Nominated Adviser and Broker to Revolymer.

Further information about the Group, including all of the information required to be disclosed pursuant to AIM Rule 26, is available on Revolymer's website, www.revolymer.com.

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

 

Panmure Gordon (UK) Limited

+44 (0) 20 7459 3600

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

 

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Ginny Pulbrook / David Dible

 

 

 

About Revolymer

 

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. The Group is generating revenues from the launch of its initial product in the US and expects to launch new products within Europe in the near term.

 

Important notice

 

This announcement has been prepared by, and is the sole responsibility of, Revolymer. No undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of Revolymer, Panmure Gordon or any of their respective directors, officers, partners, employees, agents or advisers or other person as to the accuracy completeness or fairness of the information or opinions contained in this announcement and no responsibility or liability is accepted for any such information or opinions. Nothing set out above shall exclude liability for any undertaking, representation or warranty or other assurance made fraudulently.

 

This announcement does not constitute, or form a part of, any offer or invitation to sell, allot or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall it (or any part of it) or the fact of its release, publication or distribution, form the basis of, or be relied upon in connection with, any contract or commitment for securities in any jurisdiction. Any such purchase or subscription must be made only on the basis of the information contained in the final admission document dated 4 July 2012 in connection with the admission of the ordinary shares of 1p each in the capital of Revolymer plc ("Ordinary Shares") to trading on AIM, a market operated by London Stock Exchange plc, which may be different from the information contained in this announcement and contains additional information.

The offer of the Ordinary Shares has not been, nor will they be, registered under the United States Securities Act of 1933, as amended ("Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States. The Ordinary Shares may not be offered, sold, pledged or otherwise transferred or delivered within the United States or to, or for the account or benefit of, any US person. In connection with the Placing, the Ordinary Shares are being offered and sold only outside the United States to, and for the account or benefit of, non-US persons in ''offshore transactions'' within the meaning of, and in reliance on the exemption from registration provided by, Regulation S under the Securities Act.

 

The Ordinary Shares have not been and will not be registered under the securities legislation of Canada, South Africa, the Republic of Ireland, Japan or Australia or in any country, territory or possession where to do so would contravene local securities laws or regulations and the Ordinary Shares may not be offered or sold directly or indirectly within Canada, South Africa, the Republic of Ireland, Japan or Australia or to, or for the account of benefit of, any person within Canada, South Africa, the Republic of Ireland, Japan or Australia. The distribution of this announcement in jurisdictions other than the United Kingdom may be restricted by law and therefore any person to whose attention this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws in any such jurisdictions.

 

Any prospective investor considering investing in Revolymer is recommended to seek independent financial and legal advice. 

 

Panmure Gordon is regulated and authorised in the United Kingdom by the Financial Services Authority and is acting as nominated adviser and broker to Revolymer and no one else in relation to the Placing and Admission. Panmure Gordon will not regard any person other than Revolymer as its customer in relation to the Placing and Admission and Panmure Gordon will not be responsible for providing the protections afforded to its customers to any other person or for providing advice to any other person in relation to the Placing and Admission.

 

Forward-looking statements

 

All statements, other than statements of historical facts, included in this announcement, including, without limitation, those regarding Revolymer's financial position, business strategy, plans and objectives of management for future operations or statements relating to expectations in relation to dividends or any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "plans", "will", "may", "anticipates", "would", "could" or similar expressions or the negative thereof, are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Revolymer's control that could cause the actual results, performance, achievements of or dividends paid by Revolymer to be materially different from actual results, performance or achievements, or dividend payments expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Revolymer's net asset value, present and future business strategies and income flows and the environment in which Revolymer will operate in the future.

 

These forward-looking statements speak only as of the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in Revolymer's expectations with regard thereto, any new information or any change in events, conditions or circumstances on which any such statements are based, unless required to do so by law or any appropriate regulatory authority.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCRLMATMBIMBTT
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.